Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8987441 | GENENTECH INC | Substituted polycyclic carbamoyl pyridone derivative prodrug |
Sep, 2031
(7 years from now) | |
US10392406 | GENENTECH INC | Substituted polycyclic pyridone derivatives and prodrugs thereof |
Apr, 2036
(12 years from now) | |
US10759814 | GENENTECH INC | Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof |
Aug, 2037
(13 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9815835 | GENENTECH INC | Substituted polycyclic carbamolypyridone derivative |
Jun, 2030
(6 years from now) | |
US8927710 | GENENTECH INC | Substituted polycyclic carbamoylpyridone derivative |
May, 2031
(7 years from now) | |
US10633397 | GENENTECH INC | Substituted polycyclic pyridone derivatives and prodrugs thereof |
Apr, 2036
(12 years from now) | |
US11306106 | GENENTECH INC | Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof |
Aug, 2037
(13 years from now) | |
US11261198 | GENENTECH INC | Process for preparing substituted polycyclic pyridone derivative and crystal thereof |
Sep, 2038
(14 years from now) |
Xofluza is owned by Genentech Inc.
Xofluza contains Baloxavir Marboxil.
Xofluza has a total of 8 drug patents out of which 0 drug patents have expired.
Xofluza was authorised for market use on 23 November, 2020.
Xofluza is available in for suspension;oral, tablet;oral dosage forms.
Xofluza can be used as method for post-exposure prophylaxis of influenza.
Drug patent challenges can be filed against Xofluza from 24 October, 2022.
The generics of Xofluza are possible to be released after 25 September, 2038.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Oct 24, 2023 |
Drugs and Companies using BALOXAVIR MARBOXIL ingredient
NCE-1 date: 24 October, 2022
Market Authorisation Date: 23 November, 2020
Treatment: Method for post-exposure prophylaxis of influenza
Dosage: FOR SUSPENSION;ORAL; TABLET;ORAL